Novartis has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by ...

With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss ...

Not every company is jumping onto the bandwagon and investing into weight loss drugs, however. One of the largest healthcare ...

Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. | Novartis is paying ...

BP’s program includes a novel PSMA-binding molecule that may be a potential next-generation radioligand therapy (RLT) for prostate cancer and is currently being studied in two investigator-initiated ...

Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis (IPF) but will ...

The Philippine Press Institute (PPI) together with Novartis held a hybrid seminar-workshop for journalists entitled “Anatomy ...

Novartis halted its Phase II IPF trial for LTP001, citing non-safety reasons. This move aligns with its strategy to ...

Key Insights Novartis' significant individual investors ownership suggests that the key decisions are influenced ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human Use ...